- In April 2024, Incyte Corporation announced new positive Phase III clinical trial results for its ruxolitinib cream, which significantly improved symptoms of non-segmental vitiligo in adolescents and adults. This development strengthens Incyte’s dermatology pipeline and highlights the growing innovation in topical therapies for pigmentation disorders
- In March 2024, Glenmark Pharmaceuticals launched a novel combination topical therapy for melasma under its dermatology portfolio in India. The product offers a steroid-free alternative to existing treatments and caters to the rising demand for safe, long-term pigmentation management options in the Indian market
- In February 2024, Obagi Cosmeceuticals LLC unveiled its new pigment-correcting skincare line featuring arbutin and tranexamic acid for hyperpigmentation, expanding its reach in aesthetic dermatology. The launch aims to meet consumer demand for non-invasive, cosmetic treatments across the U.S. and Europe
- In January 2024, CLINUVEL PHARMACEUTICALS LTD received regulatory clearance in Europe to market SCENESSE (afamelanotide) for the treatment of vitiligo in adult patients with Fitzpatrick skin types IV–VI. The approval marks a significant step forward in expanding treatment options for underrepresented patient populations
- In December 2023, Dr. Reddy’s Laboratories Ltd. announced the launch of its generic version of tacrolimus ointment in North America for the treatment of Pigmentation Disorders Treatment such as vitiligo and post-inflammatory hyperpigmentation. This move enhances access to cost-effective pharmacological treatments in the region
- In November 2023, Bausch Health Companies Inc. completed the acquisition of a novel skin-lightening product portfolio to strengthen its position in the aesthetic and dermatological treatment segment. The acquisition includes formulations that target melasma and sun-induced hyperpigmentation, signaling strategic market expansion
- In October 2023, Pfizer Inc. entered a collaboration with a biotech startup to develop oral melanocortin receptor modulators for pigmentation disorders. The partnership aims to pioneer systemic treatments for widespread or difficult-to-treat Pigmentation Disorders Treatment such as albinism and extensive vitiligo
